LAV Asset Management Boosts Stake in DUALITYBIO-B with 105,000 Share Purchase

Stock News

May 26

According to the latest data from the Hong Kong Stock Exchange, on May 20, LAV Asset Management (Hong Kong) Limited increased its holding in DUALITYBIO-B (09606) by 105,000 shares. The transaction was executed at a price of HK$226.0879 per share, amounting to a total consideration of approximately HK$23.74 million. Following this purchase, the firm's latest shareholding stands at approximately 11.7579 million shares, representing a 13.00% stake in the company. The transaction involved other related parties, including Shi Yi. Supplementary information indicates that LAV Star Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with a trade date of May 20, 2026 and a settlement date of May 22, 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1120438059"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120438059\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120438059?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 19:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120438059","market":"fut","top_or_hot":-1,"title":"LAV Asset Management Boosts Stake in DUALITYBIO-B with 105,000 Share Purchase","media":"Stock News","content":"<p>According to the latest data from the Hong Kong Stock Exchange, on May 20, LAV Asset Management (Hong Kong) Limited increased its holding in DUALITYBIO-B (09606) by 105,000 shares. The transaction was executed at a price of HK$226.0879 per share, amounting to a total consideration of approximately HK$23.74 million. Following this purchase, the firm's latest shareholding stands at approximately 11.7579 million shares, representing a 13.00% stake in the company. The transaction involved other related parties, including Shi Yi. Supplementary information indicates that LAV Star Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with a trade date of May 20, 2026 and a settlement date of May 22, 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LAV Asset Management Boosts Stake in DUALITYBIO-B with 105,000 Share Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLAV Asset Management Boosts Stake in DUALITYBIO-B with 105,000 Share Purchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-26 19:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the latest data from the Hong Kong Stock Exchange, on May 20, LAV Asset Management (Hong Kong) Limited increased its holding in DUALITYBIO-B (09606) by 105,000 shares. The transaction was executed at a price of HK$226.0879 per share, amounting to a total consideration of approximately HK$23.74 million. Following this purchase, the firm's latest shareholding stands at approximately 11.7579 million shares, representing a 13.00% stake in the company. The transaction involved other related parties, including Shi Yi. Supplementary information indicates that LAV Star Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with a trade date of May 20, 2026 and a settlement date of May 22, 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2543165471.USD","symbol_name":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1120438059","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120438059","pubTimestamp":1779795502,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to the latest data from the Hong Kong Stock Exchange, on May 20, LAV Asset Management (Hong Kong) Limited increased its holding in DUALITYBIO-B (09606) by 105,000 shares. The transaction...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","BK1161":"生物科技","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","EWH":"香港ETF-iShares MSCI","09606":"映恩生物-B","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元"},"translate_title":"LAV Asset Management购买105,000股股票增持DUALITYBIO-B股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1,"EWH":1},"content_text":"According to the latest data from the Hong Kong Stock Exchange, on May 20, LAV Asset Management (Hong Kong) Limited increased its holding in DUALITYBIO-B (09606) by 105,000 shares. The transaction was executed at a price of HK$226.0879 per share, amounting to a total consideration of approximately HK$23.74 million. Following this purchase, the firm's latest shareholding stands at approximately 11.7579 million shares, representing a 13.00% stake in the company. The transaction involved other related parties, including Shi Yi. Supplementary information indicates that LAV Star Limited and LAV Star Opportunities Limited purchased 52,500 and 52,500 shares of Duality Biotherapeutics, Inc.–B, respectively, with a trade date of May 20, 2026 and a settlement date of May 22, 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}